Who is sponsoring NCT01090973?

NCT01090973 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What condition does NCT01090973 study?

NCT01090973 studies Non-Hodgkin's Lymphoma.

What is the status of NCT01090973?

NCT01090973 is currently TERMINATED.

Last reviewed 2013-11-21 · How we verify

Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

NCT01090973 Phase 2 TERMINATED Results posted

The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).

Details

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 2
Status	TERMINATED
Enrolment	1
Start date	2010-03
Completion	2011-03

Conditions

Non-Hodgkin's Lymphoma

Interventions

LBH589

Primary outcomes

Number of Participants With Desired Response — 8 weeks (2 cycles) unless treatment continues due to partial or complete response
Investigators intended to assess the rate of overall and complete response by World Health Organization (WHO) classification in patients with relapsed or refractory aggressive mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). WHO Performance Scale Measures levels of patient capability: 0 Normal activity; 1 Symptoms, but nearly fully ambulatory; 2 Some bed time, but needs to be in bed \<50% of normal daytime; 3 Needs to be in bed \>50% of normal daytime; 4 Unable to get out of bed.

Countries

United States